Austin Health

Title
Onco-miR-21 Promotes Stat3-Dependent Gastric Cancer Progression.
Publication Date
2022-01-06
Author(s)
Tse, Janson
Pierce, Thomas
Carli, Annalisa L E
Alorro, Mariah G
Thiem, Stefan
Marcusson, Eric G
Ernst, Matthias
Buchert, Michael
Subject
EMT
Stat3
TME
antagomir
miR-21
stomach tumor
Type of document
Journal Article
OrcId
0000-0003-2672-0148
0000-0002-6399-1177
DOI
10.3390/cancers14020264
Abstract
MicroRNA-21 (miR-21) is a small, non-coding RNA overexpressed in gastric cancer and many other solid malignancies, where it exhibits both pro-and anti-tumourigenic properties. However, the pathways regulating miR-21 and the consequences of its inhibition in gastric cancer remain incompletely understood. By exploiting the spontaneous Stat3-dependent formation of inflammation-associated gastric tumors in Gp130F/F mice, we functionally established miR-21 as a Stat3-controlled driver of tumor growth and progression. We reconciled our discoveries by identifying several conserved Stat3 binding motifs upstream of the miR-21 gene promoter, and showed that the systemic administration of a miR-21-specific antisense oligonucleotide antagomir reduced the established gastric tumor burden in Gp130F/F mice. We molecularly delineated the therapeutic benefits of miR-21 inhibition with the functional restoration of PTEN in vitro and in vivo, alongside an attenuated epithelial-to-mesenchymal transition and the extracellular matrix remodeling phenotype of tumors. We corroborated our preclinical findings by correlating high STAT3 and miR-21 expression with the reduced survival probability of gastric cancer patients. Collectively, our results provide a molecular framework by which miR-21 mediates inflammation-associated gastric cancer progression, and establish miR-21 as a robust therapeutic target for solid malignancies characterized by excessive Stat3 activity.
Link
Citation
Cancers 2022; 14(2): 264
Jornal Title
Cancers
ISSN
2072-6694

Files:

NameSizeformatDescriptionLink